The study by Tong et al. examines the clinical outcomes of 131 patients with chronic post-transfusion hepatitis C, evaluated between February 1980 and June 1994. The mean age at initial evaluation was 57 years, with a mean age at the time of the blood transfusion being 35 years. The mean follow-up duration was 3.9 years. Common initial symptoms included fatigue (67.2%) and hepatomegaly (67.9%). The majority of patients (51.1%) had cirrhosis, while 20.6% had chronic hepatitis, 22.9% had chronic active hepatitis, and 5.3% had hepatocellular carcinoma. Hepatocellular carcinoma developed in an additional seven patients, on average 36 months after the initial visit. During follow-up, 20 patients (15.3%) died, including 8 from cirrhosis complications, 11 from hepatocellular carcinoma, and 1 from pneumonia. The study concludes that chronic post-transfusion hepatitis C is a progressive disease that can lead to death from liver failure or hepatocellular carcinoma. Screening blood products for hepatitis C and antiviral therapy for infected individuals are recommended to reduce the incidence of post-transfusion HCV infection and halt the progression of chronic liver disease.The study by Tong et al. examines the clinical outcomes of 131 patients with chronic post-transfusion hepatitis C, evaluated between February 1980 and June 1994. The mean age at initial evaluation was 57 years, with a mean age at the time of the blood transfusion being 35 years. The mean follow-up duration was 3.9 years. Common initial symptoms included fatigue (67.2%) and hepatomegaly (67.9%). The majority of patients (51.1%) had cirrhosis, while 20.6% had chronic hepatitis, 22.9% had chronic active hepatitis, and 5.3% had hepatocellular carcinoma. Hepatocellular carcinoma developed in an additional seven patients, on average 36 months after the initial visit. During follow-up, 20 patients (15.3%) died, including 8 from cirrhosis complications, 11 from hepatocellular carcinoma, and 1 from pneumonia. The study concludes that chronic post-transfusion hepatitis C is a progressive disease that can lead to death from liver failure or hepatocellular carcinoma. Screening blood products for hepatitis C and antiviral therapy for infected individuals are recommended to reduce the incidence of post-transfusion HCV infection and halt the progression of chronic liver disease.